CTI Announces That The EORTC Completes Enrollment In Phase II Clinical Trial Of Brostallicin
Cell Therapeutics, Inc.'s (CTI) (NASDAQ and MTA: CTIC) subsidiary Systems Medicine (SM) has announced that planned enrollment is complete in the European Organization for Research and Treatment of Cancer (EORTC) randomized phase II clinical trial of brostallicin in patients with newly diagnosed advanced or metastatic soft tissue sarcoma who have had no prior chemotherapy. The primary endpoint of the trial is progression-free survival at six months.
Saturday, August 16, 2008
Bacteria In Urine Could Be A Starting Point To Your Misery
After treatment, it is advisable to always regularly undergo urine testing with your doctor. This will help you and the doctor to always know whether the amount of bacteria in your urine is per what is recommended or not. What usually happens is that,urine samples are asked for by the doctor weekly and then tested to see whether they contain bacteria or not. When the doctor notices that there is are growing pattern, proper medication is then prescribed to you. If the pattern is normal, nothing is then done.
Subscribe to:
Posts (Atom)
